CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus.
carotid insufficiency
bevacizumab
coagulopathy
bevacizumab
poorly controlled diabetes mellitus
bevacizumab